Hyderabad: Lee Pharma Ltd, an integrated Pharmaceutical company based in Hyderabad, on Wednesday announced it has entered into a non-exclusive licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT) for manufacture and commercialization of 2-DG (2-Deoxy-D-Glucose), an anti-Covid drug.
The drug, found to help speed up recovery and reduce oxygen dependence, was already launched in the form of sachets by Hyderabad-based pharmaceutical giant Dr. Reddy’s laboratories in India, Lee pharma said in a release here.
Under the agreement, Lee Pharma gets non-exclusive license for the process knowhow for synthesis of 2 – DG and will file the application for getting the approval from DCGI, New Delhi.
Lee Pharma will manufacture and commercialize the 2-DG sachets from their formulation facility located at Duvvada SEZ in Visakhapatnam district of Andhra Pradesh.
Lee Pharma API manufacturing facility as well as formulation facilities are having the accreditations by the global regulatory agencies.
Lee Pharma Director Raghumitra Alla, said, “This collaboration with CSIR-IICT for 2-DG (2-Deoxy-D-Glucose) API is part of our broader strategy for enhancing Covid-19 treatment options.
Lee Pharma is already manufacturing the Favipiravir API as well as the tablets and supplying to various customers in India which is being widely used in the mild to moderate Covid–19 treatment.
CSIR-IICTis well-known for its high quality research and development of various new molecules and we feel proud to be associated with them.